Related Experiment Video
Updated: Jul 26, 2025
Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells
Published on: September 1, 2010
Preventing recurrence in Sonic Hedgehog Subgroup Medulloblastoma using the OLIG2 inhibitor CT-179
Yuchen Li1,2,3, Chaemin Lim2,4,5, Taylor Dismuke2,6
1QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.
Abstract:
Recurrence is the primary life-threatening complication for medulloblastoma (MB). In Sonic Hedgehog (SHH)-subgroup MB, OLIG2-expressing tumor stem cells drive recurrence. We investigated the anti-tumor potential of the small-molecule OLIG2 inhibitor CT-179, using SHH-MB patient-derived organoids, patient-derived xenograft (PDX) tumors and mice genetically-engineered to develop SHH-MB. CT-179 disrupted OLIG2 dimerization, DNA binding and phosphorylation and altered tumor cell cycle kinetics in vitro and in vivo, increasing differentiation and apoptosis. CT-179 increased survival time in GEMM and PDX models of SHH-MB, and potentiated radiotherapy in both organoid and mouse models, delaying post-radiation recurrence. Single cell transcriptomic studies (scRNA-seq) confirmed that CT-179 increased differentiation and showed that tumors up-regulated Cdk4 post-treatment. Consistent with increased CDK4 mediating CT-179 resistance, CT-179 combined with CDK4/6 inhibitor palbociclib delayed recurrence compared to either single-agent. These data show that targeting treatment-resistant MB stem cell populations by adding the OLIG2 inhibitor CT-179 to initial MB treatment can reduce recurrence.
Insights
The small-molecule OLIG2 inhibitor CT-179 shows promise in treating Sonic Hedgehog medulloblastoma (SHH-MB) by targeting tumor stem cells. Combining CT-179 with other therapies may reduce recurrence and improve survival in SHH-MB patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Recurrence is a major threat in medulloblastoma (MB).
- Sonic Hedgehog (SHH)-subgroup MB recurrence is driven by OLIG2-expressing tumor stem cells.
Approach:
- Investigated the OLIG2 inhibitor CT-179 in SHH-MB patient-derived organoids, xenografts, and genetically engineered mouse models.
- Assessed CT-179's effects on OLIG2 function, cell cycle, differentiation, and apoptosis in vitro and in vivo.
- Utilized single-cell transcriptomics (scRNA-seq) to analyze treatment response and identify resistance mechanisms.
Key Points:
- CT-179 disrupted OLIG2 dimerization, DNA binding, and phosphorylation, leading to increased differentiation and apoptosis.
- CT-179 improved survival in SHH-MB models and potentiated radiotherapy, delaying recurrence.
- Tumors upregulated CDK4 post-CT-179 treatment, suggesting a resistance mechanism.
Conclusions:
- CT-179 demonstrates anti-tumor potential against SHH-MB by targeting OLIG2-expressing stem cells.
- Combination therapy with CT-179 and a CDK4/6 inhibitor (palbociclib) further delayed recurrence, overcoming CT-179 resistance.
- Adding CT-179 to initial medulloblastoma treatment may reduce recurrence by targeting resistant stem cell populations.
